Altai Protocol Library
1041 protocols and counting
All protocols with references and links
All protocols reviewed by a Medical Oncologist/Hematologist
All protocols in major guidelines included
Ability to create your own protocols
New Drug: Dostarlimab for advanced dMMR endometrial cancer
Study: Open-label phase I study (GARNET) Recurrent or advanced endometrial cancer that progressed on/after platinum-based regimen Dostarlimab in MMR deficient (dMMR, n = 103) and MMR proficient (MMRp, n =
New Reference: Sacituzumab govitecan for metastatic triple-negative breast cancer
Study: Open-label, randomized phase III trial (ASCENT) Metastatic triple-negative breast cancer, relapsed or refractory to >=2 regimens (had to include a taxane) Sacituzumab govitecan (n=235) vs. single-agent chemotherapy [eribulin, vinorelbine,
New Protocol: Trastuzumab deruxtecan for her2+ metastatic colorectal cancer
Study: Open-label phase II trial (DESTINY-CRC01) Her2 overexpressing metastatic colorectal cancer that progressed on >=2 regimens Cohort A: IHC 3+ or ISH-positive (n=53) analyzed Trastuzumab deruxtecan 6.4 mg/kg IV q21d
New Protocol: Copanlisib + riTUXimab for indolent NHL
Study: Double-blind, randomized, placebo-controlled phase III trial (CHRONOS-3) CD20+ indolent non-Hodgkin lymphoma relapsed after last anti-CD20 containing therapy Copanlisib + riTUXimab vs. placebo + riTUXimab Efficacy: CR: 34% vs. 15%
New Protocol: Romidepsin and oral azacytidine for PTCL
Study: Multi-center, phase II study Treatment-naïve (n= 10) or relapsed/refractory (n=13) peripheral T-cell lymphoma Oral azacytidine 300 daily (d1-14) + romidepsin IV on days 8,15,22 (35 day cycle) Efficacy: CR:
New Protocol: Ivosidenib + chemotherapy for IDH-mutated AML
Study: Phase I, multi-center, open-label study Newly diagnosed acute myeloid leukemia with mutated IDH1 or IDH2 Continuous ivosidenib (mIDH1) or enasidenib (mIDH2) with induction 7 + 3 chemo Efficacy: CR:
New Indication: FOLFOX for second-line advanced biliary tract cancer
Study: Phase III, open-label, randomized trial (ABC-06) Locally advanced or metastatic biliary tract cancer with progression to CISplatin – gemcitabine FOLFOX-6 vs. active symptom control Efficacy: FOLFOX group => ORR:
New Drug: Loncastuximab tesirine for relapsed/refractory DLBCL
Study: Open-label phase II study (LOTIS-2) Relapsed/refractory diffuse large B-cell lymphoma with >=2 prior therapies Loncastuximab q3wk (N=145) Efficacy: CRR: 24.1%, ORR: 48.3% Median DoR: 10.3 mos ORR among double/triple-hit:
New Indication: Sacituzumab govitecan for advanced urothelial cancer
Study: Open-label phase II trial (TROPHY-U-01). Cohort 1 results Unresectable locally advanced or metastatic urothelial cancer progressed after CISplatin and checkpoint inhibitors Sacituzumab govitecan 10 mg/kg on days 1,8 (21d)
New Reference: Nivolumab + cabozantinib for previously untreated advanced clear cell renal cell carcinoma
Study: Randomized, open-label phase III trial (TIVO-3) Previously untreated RCC with clear cell component Cabozantinib 40 daily + nivolumab 240 q14 (n=323) vs. sunitinib 50 daily 4/6 wks (n=328), all
New Reference: Pembrolizumab for relapsed/refractory Hodgkin lymphoma
Study: Randomized, open-label phase III trial (KEYNOTE-204) Relapsed or refractory classical Hodgkin lymphoma who had received or were ineligible for auto-SCT Pembrolizumab (n=151) vs. brentuximab vedotin (n=153), both for 35
New Protocol: R-CHOP + Lenalidomide (R2-CHOP) for previously untreated ABC-type DLBCL
Study: Randomized, double-blind phase III trial (ROBUST) Previously untreated ABC-type diffuse large B cell lymphoma CD20+, Stages II-IV, cell of origin identified using nCounter Dx R-CHOP + lenalidomide x 6
New Indication: Lorlatinib for first-line ALK-positive NSCLC
Study: Randomized phase III trial (CROWN) Locally advanced or metastatic ALK-positive NSCLC Lorlatinib 100 mg daily (n=149) vs. crizotinib 250 mg BID (n=147) Efficacy: ORR: 76% vs. 58% (OR: 2.25
New Indication: Oral azacytidine for low-risk MDS
Study: Placebo-controlled phase III trial IPSS-defined low-risk MDS with anemia and thrombocytopenia Oral azacytidine 300 mg (21/28 days) vs. placebo Efficacy: RBC-Transfusion independence (TI) >56 days: 30.8% vs. 11.1% (OR:
New Indication: Adjuvant nivolumab for esophageal / GE junction cancer
Study: Randomized, double-blind phase III trial (CheckMate 577) Esophageal or GE junction cancer (adeno or SCC) pts who received neoadjuvant chemoRT => undergone R0 resection during which pathological residual disease
New Drug: Melphalan flufenamide and dexamethasone for relapsed and refractory myeloma
Study: Single-arm, phase II trial (HORIZON) Multiple myeloma with >2 prior lines (including IMiD and proteasome inhibitor) and refractory to pomalidomide and/or anti-CD38 Ab Monthly melflufen + weekly dexamethasone until
New Drug: Tivozanib for advanced clear cell renal cell carcinoma
Study: Randomized, open-label phase III trial (TIVO-3) RCC with clear cell component with two or three previous treatments Tivozanib 1.5 mg daily (21/28 days) (n=175) vs. sorafenib 400 mg BID
New Drug: Trilaciclib to reduce frequency of chemotherapy-induced bone marrow suppression
Study: Randomized, double-blind phase II trial First-line for metastatic small cell carcinoma CARBOplatin-Etoposide-Atezolizumab backbone. Trilaciclib vs. placebo infused once daily prior to chemo on days 1-3 Efficacy: Mean duration of
New Reference: Cabozantinib for metastatic papillary renal cell carcinoma
Study: Open label, randomized phase II trial (SWOG 1500) Metastatic papillary renal cell Ca. No prior VEGF therapy Efficacy: Cabozantinib (n=44) vs. sunitinib (n=46) vs. crizotinib vs. savolitinib (latter two